TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given an average rating of “Hold” by the twelve brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $121.10.

A number of research firms have weighed in on TMDX. Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a report on Friday, September 11th. Piper Sandler restated an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Stifel Nicolaus lifted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th.

Insider Activity

In other news, Director David Weill bought 1,336 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were acquired at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its stake in TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after buying an additional 322,353 shares during the last quarter. Geode Capital Management LLC grew its position in shares of TransMedics Group by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after acquiring an additional 2,903 shares during the last quarter. Braidwell LP increased its holdings in shares of TransMedics Group by 85.1% in the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after acquiring an additional 280,324 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of TransMedics Group by 5.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock valued at $51,355,000 after acquiring an additional 26,969 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of TransMedics Group by 6.1% in the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock valued at $34,271,000 after acquiring an additional 29,500 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.6%

TMDX opened at $87.56 on Thursday. TransMedics Group has a one year low of $60.10 and a one year high of $156.00. The company has a market cap of $3.03 billion, a P/E ratio of 22.51, a PEG ratio of 1.21 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The business’s 50-day simple moving average is $82.97 and its 200-day simple moving average is $89.26.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.92 EPS. As a group, equities research analysts expect that TransMedics Group will post 1.46 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.